397883-78-2

Upstream product

• 397883-79-3 α-bromo-N-(2,4-dimethoxybenzyl)-N-methylacetamide 
• 326473-17-0 (4-S)-4-benzyl-3-[3-(4-tert-butoxyphenyl)-propionyl]-oxazolidin-2-one 
• 21323-98-8 3-(4-tert-butoxyphenyl)-propionic acid 
• 155904-35-1 3-(4-tert-butoxy-phenyl)-acrylic acid 
• 60876-70-2 4-tert-butoxybromobenzene 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 

Downstream Products

• 326473-19-2 (2R)-2-(4-tert-butoxybenzyl)-N-(2,4-dimethoxybenzyl)-N-methylsuccinamic acid benzyl ester 
• 397883-85-1 (2S,3S)-2-[(S)-4-Benzyloxycarbonyl-2-((S)-4-benzyloxycarbonyl-2-{(R)-3-[4-(bis-benzyloxy-phosphoryloxy)-phenyl]-2-methylcarbamoylmethyl-propionylamino}-butyrylamino)-butyrylamino]-3-methyl-pentanoic acid benzyl ester 
• 397883-83-9 (2R)-2-[4-(bis-benzyloxy-phosphoryloxy)-benzyl]-N-methyl-succinamic acid 
• 326473-20-5 (2R)-2-(4-hydroxybenzyl)-N-methyl-succinamic acid 

Relevant academic research and scientific papers

Use of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide mimics in SH2 antagonists

Novel conformationally constrained phosphotyrosine pseudopeptide derivatives of the tetrapeptide pY-E-E-I were prepared and evaluated as SH2 binding antagonists. (C) 2000 Elsevier Science Ltd.